{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:18:53Z","timestamp":1788963533061,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hong Kong Research Grants Council, General Research Fund","award":["17108621"],"award-info":[{"award-number":["17108621"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40264-026-01684-4","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:07:26Z","timestamp":1781528846000},"page":"1161-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Wei","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowie P. Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinko Tsz Lam","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia T. H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangrui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caige","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent K. C.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei Hang Edmund","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing Fung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya El","family":"Helali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H. F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina Y. M.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"14","key":"1684_CR1","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horvath-Puho E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959\u201369.","journal-title":"Blood"},{"key":"1684_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100739","volume":"34","author":"HT Sorensen","year":"2023","unstructured":"Sorensen HT, Pedersen L, van Es N, Buller HR, Horvath-Puho E. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur. 2023;34:100739.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"1684_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.acvd.2023.11.009","volume":"117","author":"S Laporte","year":"2024","unstructured":"Laporte S, Benhamou Y, Bertoletti L, Frere C, Hanon O, Couturaud F, et al. Management of cancer-associated thromboembolism in vulnerable population. Arch Cardiovasc Dis. 2024;117(1):45\u201359.","journal-title":"Arch Cardiovasc Dis"},{"issue":"15","key":"1684_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729\u201335.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1684_CR5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062\u201372.","journal-title":"Am J Med"},{"issue":"2","key":"1684_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146\u201353.","journal-title":"N Engl J Med"},{"issue":"7","key":"1684_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677\u201386.","journal-title":"JAMA"},{"issue":"5","key":"1684_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496\u2013520.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1684_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023;34(5):452\u201367.","journal-title":"Ann Oncol"},{"issue":"17","key":"1684_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599\u2013607.","journal-title":"N Engl J Med"},{"issue":"7","key":"1684_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"1684_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36304","volume":"4","author":"DY Chen","year":"2021","unstructured":"Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, et al. Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism. JAMA Netw Open. 2021;4(2):e2036304.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1684_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ajh.25059","volume":"93","author":"MB Streiff","year":"2018","unstructured":"Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018;93(5):664\u201371.","journal-title":"Am J Hematol"},{"issue":"21","key":"1684_CR14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e160","volume":"34","author":"JH Lee","year":"2019","unstructured":"Lee JH, Oh YM, Lee SD, Lee JS. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. J Korean Med Sci. 2019;34(21):e160.","journal-title":"J Korean Med Sci"},{"issue":"24","key":"1684_CR15","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","volume":"4","author":"A Leader","year":"2020","unstructured":"Leader A, Hamulyak EN, Carney BJ, Avrahami M, Knip JJ, Rozenblatt S, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv. 2020;4(24):6291\u20137.","journal-title":"Blood Adv"},{"issue":"3","key":"1684_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahe I, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781\u201390.","journal-title":"Chest"},{"issue":"3","key":"1684_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11239-019-01871-4","volume":"48","author":"Y Dong","year":"2019","unstructured":"Dong Y, Wang Y, Ma RL, Liu M, Gao JZ, Su WY, et al. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis. J Thromb Thrombolysis. 2019;48(3):400\u201312.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1684_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.21037\/atm-20-8156","volume":"9","author":"X Song","year":"2021","unstructured":"Song X, Liu Z, Zeng R, Shao J, Liu B, Zheng Y, et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Ann Transl Med. 2021;9(2):162.","journal-title":"Ann Transl Med."},{"key":"1684_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1684_CR20","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 24 May 2026."},{"issue":"6","key":"1684_CR21","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s11239-024-02992-1","volume":"57","author":"M Linder","year":"2024","unstructured":"Linder M, Ekbom A, Brobert G, Vogtlander K, Balabanova Y, Becattini C, et al. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study. J Thromb Thrombolysis. 2024;57(6):973\u201383.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"1684_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/a-2259-0662","volume":"125","author":"AT Cohen","year":"2025","unstructured":"Cohen AT, Wallenhorst C, Rivera M, Ay C, Schaefer B, Abdelgawwad K, et al. Comparison of clinical outcomes in patients with active cancer receiving rivaroxaban or low-molecular-weight heparin: the OSCAR-UK study. Thromb Haemost. 2025;125(3):265\u201377.","journal-title":"Thromb Haemost"},{"issue":"7109","key":"1684_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"1684_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"2","key":"1684_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411\u201321.","journal-title":"J Thromb Haemost"},{"key":"1684_CR26","doi-asserted-by":"crossref","unstructured":"Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost. 2021;121(3):383\u201395.","DOI":"10.1055\/s-0040-1718728"},{"key":"1684_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.thromres.2023.04.009","volume":"226","author":"A Cohen","year":"2023","unstructured":"Cohen A, Noxon V, Dhamane A, Bruette R, Shah S, Hines DM, et al. Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer. Thromb Res. 2023;226:117\u201326.","journal-title":"Thromb Res"},{"issue":"6","key":"1684_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.6004\/jnccn.2024.7016","volume":"22","author":"AT Cohen","year":"2024","unstructured":"Cohen AT, Dhamane AD, Liu X, Singh R, Han S, Stellhorn R, et al. Effectiveness and safety of extended treatment spixaban versus low-molecular-weight heparin in cancer-associated venous thromboembolism. J Natl Compr Canc Netw. 2024;22(6):397\u2013403.","journal-title":"J Natl Compr Canc Netw"},{"issue":"20","key":"1684_CR29","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1684_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12288-017-0895-8","volume":"34","author":"A Chaudhury","year":"2018","unstructured":"Chaudhury A, Balakrishnan A, Thai C, Holmstrom B, Nanjappa S, Ma Z, et al. The efficacy and safety of rivaroxaban and dalteparin in the treatment of cancer associated venous thrombosis. Indian J Hematol Blood Transfus. 2018;34(3):530\u20134.","journal-title":"Indian J Hematol Blood Transfus."},{"issue":"2","key":"1684_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/1078155217739683","volume":"25","author":"JR Signorelli","year":"2019","unstructured":"Signorelli JR, Gandhi AS. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study. J Oncol Pharm Pract. 2019;25(2):362\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"1684_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-020-00221-2","volume":"18","author":"A Faqah","year":"2020","unstructured":"Faqah A, Sheikh H, Bakar MA, Tayyaab F, Khawaja S. Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre. Thromb J. 2020;18:8.","journal-title":"Thromb J"},{"issue":"2","key":"1684_CR33","doi-asserted-by":"publisher","first-page":"829","DOI":"10.21873\/invivo.11845","volume":"34","author":"JH Kim","year":"2020","unstructured":"Kim JH, Seo S, Kim KP, Chang HM, Ryoo BY, Yoo C, et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. In Vivo. 2020;34(2):829\u201337.","journal-title":"In Vivo"},{"issue":"2","key":"1684_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","volume":"5","author":"CI Coleman","year":"2023","unstructured":"Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M, et al. Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism. JACC CardioOncol. 2023;5(2):189\u2013200.","journal-title":"JACC CardioOncol."},{"issue":"1","key":"1684_CR35","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1055\/s-0037-1603924","volume":"1","author":"W Ageno","year":"2017","unstructured":"Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE. TH Open. 2017;1(1):e33-42.","journal-title":"TH Open."},{"key":"1684_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13074","author":"B Simmons","year":"2018","unstructured":"Simmons B, Wysokinski W, Saadiq RA, Bott-Kitslaar D, Henkin S, Casanegra A, et al. Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. Eur J Haematol. 2018. https:\/\/doi.org\/10.1111\/ejh.13074. ([Epub ahead of print]).","journal-title":"Eur J Haematol"},{"issue":"3","key":"1684_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000499895","volume":"98","author":"JH Lee","year":"2019","unstructured":"Lee JH, Hyun DG, Choi CM, Lee JC, Kim WS, Oh YM, et al. A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer. Respiration. 2019;98(3):203\u201311.","journal-title":"Respiration"},{"issue":"3","key":"1684_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.22465\/kjuo.2019.17.3.178","volume":"17","author":"JH Lee","year":"2019","unstructured":"Lee JH, You D, Lee S-D, Oh Y-M, Lee JS. A study on the efficacy and safety of rivaroxaban in urologic cancer-associated venous thromboembolism. Korean J Urol Oncol. 2019;17(3):178\u201385.","journal-title":"Korean J Urol Oncol"},{"issue":"1","key":"1684_CR39","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e10","volume":"31","author":"JH Lee","year":"2020","unstructured":"Lee JH, Lee JH, Jo KW, Huh JW, Oh YM, Lee JS. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. J Gynecol Oncol. 2020;31(1):e10.","journal-title":"J Gynecol Oncol"},{"issue":"11","key":"1684_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1159\/000545976","volume":"48","author":"M Sinn","year":"2025","unstructured":"Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Sudhoff T, et al. CONKO-011\/AIO-SUP-0115\/ass.: rivaroxaban compared to low molecular weight heparin in cancer patients with acute venous thromboembolism. Oncol Res Treat. 2025;48(11):685\u201395.","journal-title":"Oncol Res Treat"},{"key":"1684_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","volume":"150","author":"JA Ross","year":"2017","unstructured":"Ross JA, Miller MM, Rojas Hernandez CM. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86\u20139.","journal-title":"Thromb Res"},{"key":"1684_CR42","doi-asserted-by":"crossref","unstructured":"Alzghari SK, Seago SE, Garza JE, Hashimie YF, Baty KA, Evans MF, et al. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: the Re-CLOT study. J Oncol Pharm Pract. 2018;24(7):494\u2013500.","DOI":"10.1177\/1078155217718382"},{"issue":"4","key":"1684_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/1078155218757856","volume":"25","author":"MK Phelps","year":"2019","unstructured":"Phelps MK, Wiczer TE, Erdeljac HP, Van Deusen KR, Porter K, Philips G, et al. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer: a real world experience. J Oncol Pharm Pract. 2019;25(4):793\u2013800.","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"1684_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.25604","volume":"94","author":"WE Wysokinski","year":"2019","unstructured":"Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185\u201392.","journal-title":"Am J Hematol"},{"key":"1684_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2021.03.026","volume":"202","author":"A Douros","year":"2021","unstructured":"Douros A, Filliter C, Azoulay L, Tagalakis V. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. Thromb Res. 2021;202:128\u201333.","journal-title":"Thromb Res"},{"issue":"5","key":"1684_CR46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0897190019896500","volume":"34","author":"LM Fovel","year":"2021","unstructured":"Fovel LM, Seabury RW, Miller CD, Darko W, Probst LA, Horvath L. Safety and efficacy of direct oral anticoagulant therapy in patients with cancer. J Pharm Pract. 2021;34(5):710\u20134.","journal-title":"J Pharm Pract"},{"issue":"3","key":"1684_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-023-02858-y","volume":"56","author":"T Guan","year":"2023","unstructured":"Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, et al. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies. J Thromb Thrombolysis. 2023;56(3):439\u201346.","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"1684_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25283","volume":"6","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Fuentes H, Deng Y, Naqvi SAA, Yao X, Sangaralingham LR, et al. Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw Open. 2023;6(7):e2325283.","journal-title":"JAMA Netw Open"},{"issue":"22","key":"1684_CR49","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924\u201333.","journal-title":"JAMA"},{"key":"1684_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00353","volume":"10","author":"K Kengkla","year":"2024","unstructured":"Kengkla K, Nathisuwan S, Sripakdee W, Saelue P, Sengnoo K, Sookprasert A, et al. Trends in anticoagulant utilization and clinical outcomes for cancer-associated thrombosis: a multicenter cohort study in Thailand\u2019s upper-middle-income country setting. JCO Glob Oncol. 2024;10:e2300353.","journal-title":"JCO Glob Oncol."},{"key":"1684_CR51","doi-asserted-by":"crossref","unstructured":"Chung J, Park J, Chin-Hon J, Akerman M, Hindenburg A. Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: a retrospective analysis. J Oncol Pharm Pract. 2025:10781552251331559.","DOI":"10.1177\/10781552251331559"},{"issue":"4","key":"1684_CR52","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374.","journal-title":"Blood Adv"},{"issue":"7","key":"1684_CR53","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347.","journal-title":"Lancet Oncol"},{"key":"1684_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00773","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Lv H, Li D, Chen C, Gu G, Sun Y, et al. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. Front Pharmacol. 2019;10:773.","journal-title":"Front Pharmacol"},{"key":"1684_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620940046","volume":"27","author":"MFH Mohamed","year":"2021","unstructured":"Mohamed MFH, ElShafei MN, Ahmed MB, Abdalla LO, Ahmed I, Elzouki AN, et al. The net clinical benefit of rivaroxaban compared to low-molecular-weight heparin in the treatment of cancer-associated thrombosis: systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021;27:1076029620940046.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"1684_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1684_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12736","volume":"6","author":"J Trujillo-Santos","year":"2022","unstructured":"Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gomez-Cuervo C, Ballaz A, Braester A, et al. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: the RIETECAT study. Res Pract Thromb Haemost. 2022;6(4):e12736.","journal-title":"Res Pract Thromb Haemost."},{"issue":"3","key":"1684_CR58","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11239-023-02926-3","volume":"57","author":"D Fredman","year":"2024","unstructured":"Fredman D, McNeil R, Eldar O, Leader A, Gafter-Gvili A, Avni T. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: a systematic review and meta-analysis of observational studies. J Thromb Thrombolysis. 2024;57(3):453\u201365.","journal-title":"J Thromb Thrombolysis"},{"issue":"20","key":"1684_CR59","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1002\/cam4.4241","volume":"10","author":"YS Lin","year":"2021","unstructured":"Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban. Cancer Med. 2021;10(20):7079\u201388.","journal-title":"Cancer Med"},{"issue":"15","key":"1684_CR60","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","volume":"3","author":"MR Aryal","year":"2019","unstructured":"Aryal MR, Gosain R, Donato A, Yu H, Katel A, Bhandari Y, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3(15):2381\u20137.","journal-title":"Blood Adv"},{"issue":"2","key":"1684_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11239-014-1102-5","volume":"39","author":"S Mantha","year":"2015","unstructured":"Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2015;39(2):155\u201365.","journal-title":"J Thromb Thrombolysis"},{"key":"1684_CR62","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.thromres.2020.06.035","volume":"193","author":"J Trujillo-Santos","year":"2020","unstructured":"Trujillo-Santos J, Beroiz P, Moustafa F, Alonso A, Morejon E, Lopez-Reyes R, et al. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res. 2020;193:160\u20135.","journal-title":"Thromb Res"},{"issue":"6","key":"1684_CR63","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","volume":"5","author":"L Bertoletti","year":"2023","unstructured":"Bertoletti L, Madridano O, Jimenez D, Muriel A, Bikdeli B, Ay C, et al. Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC Cardio Oncol. 2023;5(6):758\u201372.","journal-title":"JACC Cardio Oncol."},{"issue":"4","key":"1684_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11239-023-02791-0","volume":"55","author":"R Robinson","year":"2023","unstructured":"Robinson R, Spectre G, Lishner M, Sharabi O, Robinson E, Hamburger Avnery O, et al. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies. J Thromb Thrombolysis. 2023;55(4):729\u201336.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"1684_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1078155217690922","volume":"24","author":"MD Nicklaus","year":"2018","unstructured":"Nicklaus MD, Ludwig SL, Kettle JK. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. J Oncol Pharm Pract. 2018;24(3):185\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"1684_CR66","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4251\/wjgo.v11.i10.866","volume":"11","author":"A Recio-Boiles","year":"2019","unstructured":"Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol. 2019;11(10):866\u201376.","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"1684_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11239-019-02032-3","volume":"50","author":"JD Guo","year":"2020","unstructured":"Guo JD, Hlavacek P, Poretta T, Wygant G, Lane D, Gorritz M, et al. Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. J Thromb Thrombolysis. 2020;50(2):386\u201394.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"1684_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/jth.15153","volume":"19","author":"JK Schaefer","year":"2021","unstructured":"Schaefer JK, Li M, Wu Z, Basu T, Dorsch MP, Barnes GD, et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost. 2021;19(1):212\u201320.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1684_CR69","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/ijgc-2019-000284","volume":"29","author":"Z Marchocki","year":"2019","unstructured":"Marchocki Z, Norris L, O\u2019Toole S, Gleeson N, Saadeh FA. Patients\u2019 experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynecological cancer: a prospective observational study. Int J Gynecol Cancer. 2019;29(4):802\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"1684_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2019.05.012","volume":"180","author":"A Li","year":"2019","unstructured":"Li A, Manohar PM, Garcia DA, Lyman GH, Steuten LM. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019;180:37\u201342.","journal-title":"Thromb Res"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01684-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01684-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01684-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:02:33Z","timestamp":1788962553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01684-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01684-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Esther W. Chan has received grants from the Research Grants Council of the Hong Kong SAR, Research Fund Secretariat of the Health Bureau of the Hong Kong SAR, National Natural Science Fund of China, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Novartis, Amgen, AstraZeneca, Takeda, the RGA Reinsurance Company, Narcotics Division of the Security Bureau of the Hong Kong SAR, and the National Health and Medical Research Council Australia; consulting fees from AstraZeneca, Pfizer, and Novartis; and an honorarium from the Hospital Authority of the Hong Kong SAR. Wei Kang, Bowie P.Y. Lam, Rinko Tsz Lam Lau, Silvia T.H. Li, Kangrui Wu, Yue Wei, Yu Yang, Kyung Jin Lee, Caige Huang, Vincent K.C. Yan, Hei Hang Edmund Yiu, Shing Fung Lee, Aya El Helali, Victor H.F. Lee, Stephen L. Chan, Rina Y.M. Hui, and Ka On Lam have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this meta-analysis was based on data extracted from previously published research, all the data and study materials are available in the public domain. For further discussions, we invite interested parties to contact the corresponding author.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization and design: WK and EWC; acquisition, analysis, or interpretation of data: WK, BPYL, TLL, STHL, KW, and EWC; drafting of the manuscript: WK, BPYL, and TLL; critical revision of the manuscript for important intellectual content: all authors; statistical analysis: WK, BPYL, and STHL; administrative, technical, or material support: EWC; supervision: EWC. All authors read, reviewed, and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}